Touch CMC prosthesis, exploded view of the cup, stem and ball components

Hand & Wrist · Dual-Mobility CMC

Touch® CMC Prosthesis

Dual-mobility trapeziometacarpal joint prosthesis for thumb-base osteoarthritis. Highly cross-linked polyethylene liner, spherical and conical cup options, 144 implant configurations, and a 116° mobility cone. Purpose-built for CMC arthroplasty, not a repurposed hip mini-implant. CE-marked Class III under EU MDR 2017/745 (notified body 2862), continuously since 2015. GESY-covered in Cyprus through OrganoGEN.

Manufactured by KeriMedical SA (Medartis Group) (Geneva, Switzerland) · Distributed in Cyprus by OrganoGEN Limited

144Configurations
(6 stems × 4 cups × 6 necks)
0.5%Dislocation rate
(vs 4.2% Arpe, P=0.02)
116°Mobility cone
(dual-mobility design)
96%Implant survival
(at 5 years, n=125)
verifiedGESY-CoveredscienceDual-Mobility + HXLPEpublicCE-Marked Class IIIsupport_agentSurgical Support

In One Paragraph

The Touch® CMC Prosthesis is a dual-mobility trapeziometacarpal joint implant for thumb-base osteoarthritis (rhizarthrosis), manufactured by KeriMedical in Geneva, part of the Medartis Group. The construct combines a titanium anatomical trilobe stem (Titanium + hydroxyapatite dual coating), stainless steel cups in spherical and conical shapes (also dual-coated), and a highly cross-linked polyethylene (HXLPE) liner. 144 implant configurations (6 stems × 4 cup options × 6 neck options) let the surgeon match anatomy intra-operatively from a single tray. The dual-mobility design distributes motion across two articular surfaces and delivers a 116° mobility cone, greater than the native CMC joint. Comparative evidence reports a 0.5% dislocation rate versus 4.2% with the legacy single-mobility Arpe implant (P=0.02, Reyniers 2025), and a prospective series of 107 cases with more than 3-year follow-up reported zero dislocations (Lussiez 2021). Published implant survival is 96% at five years (Herren 2026), and the longest Touch®-specific series reports a single revision in 61 prostheses at a mean of 6.5 years (Falaise 2025). CE-marked Class III under EU MDR 2017/745 (notified body 2862), continuously since 2015; MDR certification valid through 15 February 2028. Also FDA PMA-approved (P240020, 10 July 2025). GESY-covered in Cyprus through OrganoGEN.

Overview

The Touch® CMC Prosthesis is a dual-mobility implant for the surgical treatment of trapeziometacarpal (CMC) osteoarthritis, the form of arthritis at the base of the thumb most commonly known as rhizarthrosis. The dual-mobility configuration, borrowed from total hip arthroplasty, distributes motion across two articular surfaces and is the principal reason its published dislocation rate sits below 1%. By design the Touch® prosthesis delivers a 116° mobility cone, greater than the native CMC joint, with motion distributed symmetrically when the cup is positioned in the reference orientation.

KeriMedical, the Swiss manufacturer, has built the Touch® system around 144 implant configurations. The combinatorial breakdown is: 6 stem sizes (anatomical trilobe titanium stems with a titanium and hydroxyapatite dual coating), two cup shapes (spherical or conical, in two diameters of 9 mm and 10 mm, stainless steel with the same titanium and hydroxyapatite dual coating), and six neck options (three heights of 6 mm, 8 mm and 10 mm in either straight or 15° offset configurations). The mobile bearing is a highly cross-linked polyethylene (HXLPE) liner with a 4 mm head diameter. The implant is purpose-designed for the trapeziometacarpal joint, not a repurposed hip mini-prosthesis. Touch® is the first CMC1 prosthesis on the market to offer both spherical and conical cup options, and the first dual-mobility CMC1 prosthesis to use a highly cross-linked polyethylene liner.

Touch® is CE-marked Class III under EU MDR 2017/745 (notified body 2862), continuously since 2015; current MDR certification is valid through 15 February 2028. The implant is GESY-covered in Cyprus when implanted by a participating hand surgeon at a GESY-contracted hospital. (Touch® also holds FDA Premarket Approval P240020, granted 10 July 2025 - relevant as an additional regulatory credential, not a primary positioning point for the Cypriot market.) KeriMedical has been part of the Medartis Group since July 2025 and operates as a distinct hand-and-wrist brand within the group.

OrganoGEN is the exclusive Cyprus distributor and provides surgical support at every implantation.

Indications & Contraindications

check_circleIndicated For

  • Trapeziometacarpal (CMC) osteoarthritis (rhizarthrosis)
  • Painful CMC instability after failed conservative therapy of at least six months
  • Post-traumatic CMC arthritis with preserved trapezium height
  • Revision of failed trapeziectomy with adequate bone stock

blockContraindicated For

  • Active local or systemic infection
  • Insufficient trapezial bone stock
  • Skeletal immaturity
  • Patient unable to comply with the post-operative protocol

Technical Specifications

ManufacturerKeriMedical SA, Geneva, Switzerland (Medartis Group since July 2025)
Configurations144 total (6 stems × 4 cup options × 6 neck options)
StemTitanium, anatomical trilobe section, dual coating (Titanium + hydroxyapatite). 6 sizes (XS, 0, 1, 2, 3, 4)
CupsStainless steel with dual coating (Titanium + hydroxyapatite). Two shapes (spherical, conical), two diameters (Ø9 mm and Ø10 mm). 4 total cup references
LinerHighly cross-linked polyethylene (HXLPE)
Neck and headStainless steel. 3 heights (6 mm, 8 mm, 10 mm) in straight or 15° offset configurations. Head diameter 4 mm
ArticulationDual-mobility, 116° mobility cone
Regulatory (EU)CE-marked Class III, EU MDR 2017/745, notified body 2862. Continuously CE-marked since 2015. MDR certification valid through 15 February 2028
Regulatory (US)FDA PMA P240020, 10 July 2025
Distribution in CyprusOrganoGEN Limited (exclusive)
GESY reimbursementApproved (active ZC code)

Clinical evidence

Reyniers et al. 2025

Single-surgeon comparative series, 184 Touch® prostheses against 168 of the legacy single-mobility Arpe. One dislocation with Touch® (0.5%) against seven with Arpe (4.2%), P=0.02. Overall complication rate 2.7% versus 6.5%. Implant survival 97% at 31 months.

Hand (N Y) 2025 Sep 28. PubMed 41015915
Herren et al. 2026

Registry cohort of 125 patients followed to five years. 96% implant survival at 5 years (95% CI 92 to 100). 93% of patients satisfied or very satisfied. Pain, hand function and key-pinch strength all significantly improved from baseline.

J Hand Surg Eur Vol 2026 Jul 24
Falaise and Boulat 2025

Longest published Touch®-specific follow-up. 61 prostheses at a mean of 6.5 years (range 5 to 8.8). Pain fell from 7.3 to 0.4 and key grip strength rose from 67% to 102% of the opposite side. One revision (2%), for cup loosening at seven years. All patients satisfied or very satisfied.

Hand Surg Rehabil 2025;44(3):102167
Lussiez et al. 2021

Prospective study of 107 cases with minimum 3-year follow-up. Pain VAS dropped from 7.4 to 0.8 (p<0.001), Kapandji opposition score from 8.0 to 9.4, QuickDASH from 38 to 20 (p<0.01), key-pinch strength from 3.5 kg to 5.5 kg. 95% of patients very satisfied or satisfied. Zero dislocations at minimum 3-year follow-up.

J Hand Surg Eur Vol 2021;46(9):961-967
Herren et al. 2023

Prospective cohort, 130 patients. 96% implant survival at 2 years (95% CI 90 to 99). Pain at rest fell from 5 to 0 and key-pinch strength rose from 4.5 kg to 7.0 kg. The authors recommend Touch® as the standard procedure for isolated trapeziometacarpal osteoarthritis.

PubMed 37310049
Herren et al. 2023, implant versus resection

Direct comparison against resection-suspension-interposition arthroplasty. Employed patients returned to work at a mean of 44 days after implant arthroplasty against 84 days after resection. Key-pinch strength 6.8 kg versus 3.1 kg at three months, and 7.0 kg versus 3.9 kg at one year.

J Hand Surg Eur Vol 2023 Jul 21
Marks et al. 2026

Cost-utility analysis over one year, 80 implant patients against 39 resection arthroplasty patients. Implant arthroplasty produced higher quality-adjusted life years (0.89 versus 0.85) at lower total cost (USD 26,809 versus USD 33,953), and stayed cost effective in five-year sensitivity analysis.

J Hand Surg Am 2026 Jan 28
Gonzalez-Espino et al. 2021

Retrospective series of 92 prostheses. No major complications (dislocation, fracture or loosening). Functional QuickDASH scores not significantly different from age-matched general population. Mean return to work 2.6 months.

Hand Surg Rehabil 2021;40(6):760-764
Herren et al. 2025, learning curve

338 Touch® arthroplasties analysed by cumulative sum method. Surgeons reached proficiency between case 33 and case 40, with mean operating times of 39 to 59 minutes. Two-year outcomes and revision rates were no worse for patients operated before proficiency was reached.

J Hand Surg Eur Vol 2025 Jun 9
Lyons et al. 2026

Three-round modified Delphi consensus with 16 hand surgeons and hand therapists from the UK and mainland Europe, setting postoperative best practice and return-to-activity timescales for thumb CMC joint replacement.

Bone Jt Open 2026;7(7):825-837
Abdoulaye-Diallo et al. 2026

French national hospital discharge data, 2009 to 2024, with two surveys of the French Society for Surgery of the Hand. Trapeziometacarpal arthroplasty accounted for 75.1% of all rhizarthrosis procedures in 2024, and the share of surgeons reporting a predominance of arthroplasty rose from 52.5% in 2018 to 85.9% in 2025. A study of the procedure, not of Touch® specifically.

Hand Surg Rehabil 2026;45(3):102619
KeriMedical scientific dossier, September 2026

Collects 94 publications and congress abstracts on CMC1 arthroplasty, of which 56 sit in the Touch®-specific sections, covering peer-reviewed clinical series, congress abstracts, comparisons against trapeziectomy, and pre-clinical work. Full bibliography available to qualifying surgeons on request.

Manufacturer documentation

Recovery Timeline

Days 0 to 14Immediate protection. A bulky bandage allowing restricted thumb movement, for ten to fourteen days. A post-operative radiograph is taken.
Week 2Light tasks. Return to light daily tasks at around two weeks.
Week 4Driving and moderate tasks. Return to driving and to moderate tasks at around four weeks.
Weeks 6 to 8Heavy tasks. Return to heavy manual tasks at six to eight weeks. Working patients in published series returned to work at a mean of 44 to 51 days. Timings are typical; the operating surgeon sets each patient's programme.

GESY Coverage & Pricing in Cyprus

The Touch® CMC Prosthesis is GESY-covered under an active ZC code. When implanted by a participating hand surgeon at a GESY-contracted hospital, the device cost is included in the hospital reimbursement, and patients are not billed separately for the implant.

For self-pay or international patients, OrganoGEN provides hospital quotations on request. We do not publish list prices. Request a quote with your hospital's procurement details.

Frequently asked questions

Is the Touch® CMC Prosthesis covered by GESY in Cyprus?
Yes. The Touch® CMC Prosthesis is approved for GESY reimbursement when implanted by a participating hand surgeon at a GESY-contracted hospital. The implant cost is included in the hospital reimbursement.
Who manufactures the Touch® CMC Prosthesis?
KeriMedical SA in Geneva, Switzerland. KeriMedical was founded by hand surgeons and has been part of the Medartis Group since July 2025, operating as a distinct hand-and-wrist brand within the group. OrganoGEN is the exclusive distributor in Cyprus.
What is the dislocation rate of the Touch® CMC Prosthesis?
In a single-surgeon comparative series, there was one dislocation in 184 Touch® prostheses (0.5%) against seven in 168 of the legacy single-mobility Arpe implant (4.2%), P=0.02. Overall complication rates in the same series were 2.7% for Touch® and 6.5% for Arpe (Reyniers et al. 2025, PubMed 41015915). A separate prospective study of 107 cases with more than three years of follow-up reported zero dislocations (Lussiez et al. 2021, J Hand Surg Eur Vol 46(9):961-967).
Is the Touch® implant CE-marked?
Yes. Touch® is CE-marked Class III under EU MDR 2017/745 (notified body 2862). KeriMedical has held continuous CE certification since 2015; the current MDR certificate is valid through 15 February 2028. Touch® additionally holds FDA Premarket Approval P240020 (10 July 2025) for the US market - a useful credential, not a primary positioning point for Cyprus.
Why are 144 configurations needed?
Trapeziometacarpal anatomy varies significantly between patients. The Touch® system combines 6 stem sizes, two cup shapes (spherical and conical) in two diameters, and six neck options (three heights, straight or 15° offset), yielding 144 total configurations. The surgeon matches the implant to anatomy intra-operatively from a single tray rather than committing to a fixed configuration at templating.
What is the polyethylene liner made of and why does it matter?
The Touch® liner is highly cross-linked polyethylene (HXLPE), the same polymer technology used in modern total hip replacements for improved wear resistance. KeriMedical bench testing shows the HXLPE liner retains 97.5% of its volume after 5 million test cycles (approximately ten years of regular thumb usage) compared with 91.1% for standard polyethylene. Touch® is the first dual-mobility CMC1 prosthesis to use HXLPE. Bench testing is not necessarily indicative of clinical performance, but five-to-eight-year prospective clinical follow-up data is published.
What functional improvement do patients see after Touch® CMC arthroplasty?
In the largest published prospective Touch® series with more than three years of follow-up, mean pain on a 0 to 10 visual analogue scale dropped from 7.4 to 0.8, the Kapandji thumb-opposition score improved from 8.0 to 9.4, the QuickDASH disability score improved from 38 to 20, and key-pinch strength increased from 3.5 kg to 5.5 kg. 95% of patients reported being very satisfied or satisfied with the functional outcome (Lussiez et al. 2021). A separate 92-prosthesis series reported mean return to work at 2.6 months (Gonzalez-Espino et al. 2021).
How long does a Touch® CMC prosthesis last?
Published implant survival is 96% at two years (130 patients, Herren et al. 2023) and 96% at five years (125 patients, Herren et al. 2026, 95% CI 92 to 100). The longest Touch®-specific follow-up published to date covers 61 prostheses at a mean of 6.5 years, with a single revision for cup loosening at seven years and every patient satisfied or very satisfied (Falaise and Boulat 2025). Where a prosthesis does need revising, the salvage operation is a standard trapeziectomy, and published outcomes of that salvage are comparable to a primary trapeziectomy.
How soon can patients return to work and normal activities?
In a direct comparison against resection arthroplasty, employed patients returned to work at a mean of 44 days after Touch® implant arthroplasty against 84 days after resection (Herren et al. 2023). A separate series of 179 patients reported a median of 51 days, with no significant difference between office workers and manual workers (Tchurukdichian et al. 2025). A 2026 European Delphi consensus sets the expected timescales at two weeks for light tasks, four weeks for driving and moderate tasks, and six to eight weeks for heavy tasks (Lyons et al. 2026).
How does Touch® compare with trapeziectomy?
In a comparative study (Herren et al. 2023), recovery was faster and the thumb stronger after Touch® than after trapeziectomy. Patients returned to work roughly forty days earlier and had higher key-pinch strength, 6.8 kg against 3.1 kg at three months and 7.0 kg against 3.9 kg at one year. Thumb column length is preserved rather than resected, which in a case-control study also corrected pre-existing metacarpophalangeal hyperextension without a second procedure (Schindele et al. 2025). At one year, overall hand-function scores converge between the two operations, so the case for arthroplasty rests on speed of recovery, strength and preservation of thumb length rather than on a better end point. A 2026 cost-utility analysis found implant arthroplasty both lower in total cost and higher in quality-adjusted life years than resection arthroplasty over one year (Marks et al. 2026).
Where can patients have Touch® CMC arthroplasty in Cyprus?
OrganoGEN supplies the Touch® system to GESY-contracted hospitals across Cyprus. Contact us for the current list of participating hand surgeons in Limassol, Nicosia, Larnaca, Paphos, and Famagusta.

More in Hand & Wrist

Other products OrganoGEN distributes in the Hand & Wrist category.

arrow_back
Touch® CMC Prosthesis
Hand & Wrist · Dual-Mobility CMC

Touch® CMC Prosthesis

Dual-mobility trapeziometacarpal joint prosthesis for thumb-base osteoarthritis. Highly cross-linked polyethylene liner, spherical and conical cup options, 144 implant configurations, and a 116° mobility cone. Purpose-built for CMC arthroplasty, not a repurposed hip mini-implant. CE-marked Class III under EU MDR 2017/745 (notified body 2862), continuously since 2015. GESY-covered in Cyprus through OrganoGEN.

verifiedGESY-CoveredscienceDual-Mobility + HXLPEpublicCE-Marked Class IIIsupport_agentSurgical Support
Touch CMC prosthesis, exploded view of the cup, stem and ball components
Touch CMC prosthesis, assembled implant
Touch CMC dual-mobility prosthesis, assembled implant
Touch CMC prosthesis stems, full size range
Touch CMC prosthesis instrument tray
Touch CMC prosthesis, post-operative X-ray of the thumb base
Touch CMC prosthesis, modular component range
Touch CMC prosthesis, post-operative hand X-ray
Touch CMC prosthesis stem in the metacarpal, post-operative X-ray
Touch CMC prosthesis, post-operative X-ray of the stem and cup
Touch CMC prosthesis, post-operative X-ray at the thumb base joint
Touch CMC prosthesis surgical instrument tray
Touch CMC prosthesis instrument set, loaded tray

In One Paragraph

The Touch® CMC Prosthesis is a dual-mobility trapeziometacarpal joint implant for thumb-base osteoarthritis (rhizarthrosis), manufactured by KeriMedical in Geneva, part of the Medartis Group. The construct combines a titanium anatomical trilobe stem (Titanium + hydroxyapatite dual coating), stainless steel cups in spherical and conical shapes (also dual-coated), and a highly cross-linked polyethylene (HXLPE) liner. 144 implant configurations (6 stems × 4 cup options × 6 neck options) let the surgeon match anatomy intra-operatively from a single tray. The dual-mobility design distributes motion across two articular surfaces and delivers a 116° mobility cone, greater than the native CMC joint. Comparative evidence reports a 0.5% dislocation rate versus 4.2% with the legacy single-mobility Arpe implant (P=0.02, Reyniers 2025), and a prospective series of 107 cases with more than 3-year follow-up reported zero dislocations (Lussiez 2021). Published implant survival is 96% at five years (Herren 2026), and the longest Touch®-specific series reports a single revision in 61 prostheses at a mean of 6.5 years (Falaise 2025). CE-marked Class III under EU MDR 2017/745 (notified body 2862), continuously since 2015; MDR certification valid through 15 February 2028. Also FDA PMA-approved (P240020, 10 July 2025). GESY-covered in Cyprus through OrganoGEN.

Overview

Overview

The Touch® CMC Prosthesis is a dual-mobility implant for the surgical treatment of trapeziometacarpal (CMC) osteoarthritis, the form of arthritis at the base of the thumb most commonly known as rhizarthrosis. The dual-mobility configuration, borrowed from total hip arthroplasty, distributes motion across two articular surfaces and is the principal reason its published dislocation rate sits below 1%. By design the Touch® prosthesis delivers a 116° mobility cone, greater than the native CMC joint, with motion distributed symmetrically when the cup is positioned in the reference orientation.

KeriMedical, the Swiss manufacturer, has built the Touch® system around 144 implant configurations. The combinatorial breakdown is: 6 stem sizes (anatomical trilobe titanium stems with a titanium and hydroxyapatite dual coating), two cup shapes (spherical or conical, in two diameters of 9 mm and 10 mm, stainless steel with the same titanium and hydroxyapatite dual coating), and six neck options (three heights of 6 mm, 8 mm and 10 mm in either straight or 15° offset configurations). The mobile bearing is a highly cross-linked polyethylene (HXLPE) liner with a 4 mm head diameter. The implant is purpose-designed for the trapeziometacarpal joint, not a repurposed hip mini-prosthesis. Touch® is the first CMC1 prosthesis on the market to offer both spherical and conical cup options, and the first dual-mobility CMC1 prosthesis to use a highly cross-linked polyethylene liner.

Clinical Use

Indications & Contraindications

check_circleIndicated for

  • Trapeziometacarpal (CMC) osteoarthritis (rhizarthrosis)
  • Painful CMC instability after failed conservative therapy of at least six months
  • Post-traumatic CMC arthritis with preserved trapezium height
  • Revision of failed trapeziectomy with adequate bone stock

cancelContraindicated

  • Active local or systemic infection
  • Insufficient trapezial bone stock
  • Skeletal immaturity
  • Patient unable to comply with the post-operative protocol
Technical

Technical Specifications

Manufacturer
KeriMedical SA, Geneva, Switzerland (Medartis Group since July 2025)
Configurations
144 total (6 stems × 4 cup options × 6 neck options)
Stem
Titanium, anatomical trilobe section, dual coating (Titanium + hydroxyapatite). 6 sizes (XS, 0, 1, 2, 3, 4)
Cups
Stainless steel with dual coating (Titanium + hydroxyapatite). Two shapes (spherical, conical), two diameters (Ø9 mm and Ø10 mm). 4 total cup references
Liner
Highly cross-linked polyethylene (HXLPE)
Neck and head
Stainless steel. 3 heights (6 mm, 8 mm, 10 mm) in straight or 15° offset configurations. Head diameter 4 mm
Articulation
Dual-mobility, 116° mobility cone
Regulatory (EU)
CE-marked Class III, EU MDR 2017/745, notified body 2862. Continuously CE-marked since 2015. MDR certification valid through 15 February 2028
Regulatory (US)
FDA PMA P240020, 10 July 2025
Distribution in Cyprus
OrganoGEN Limited (exclusive)
GESY reimbursement
Approved (active ZC code)
Evidence

Clinical evidence

Reyniers et al. 2025 Single-surgeon comparative series, 184 Touch® prostheses against 168 of the legacy single-mobility Arpe. One dislocation with Touch® (0.5%) against seven with Arpe (4.2%), P=0.02. Overall complication rate 2.7% versus 6.5%. Implant survival 97% at 31 months. Hand (N Y) 2025 Sep 28. PubMed 41015915
Herren et al. 2026 Registry cohort of 125 patients followed to five years. 96% implant survival at 5 years (95% CI 92 to 100). 93% of patients satisfied or very satisfied. Pain, hand function and key-pinch strength all significantly improved from baseline. J Hand Surg Eur Vol 2026 Jul 24
Falaise and Boulat 2025 Longest published Touch®-specific follow-up. 61 prostheses at a mean of 6.5 years (range 5 to 8.8). Pain fell from 7.3 to 0.4 and key grip strength rose from 67% to 102% of the opposite side. One revision (2%), for cup loosening at seven years. All patients satisfied or very satisfied. Hand Surg Rehabil 2025;44(3):102167
Lussiez et al. 2021 Prospective study of 107 cases with minimum 3-year follow-up. Pain VAS dropped from 7.4 to 0.8 (p<0.001), Kapandji opposition score from 8.0 to 9.4, QuickDASH from 38 to 20 (p<0.01), key-pinch strength from 3.5 kg to 5.5 kg. 95% of patients very satisfied or satisfied. Zero dislocations at minimum 3-year follow-up. J Hand Surg Eur Vol 2021;46(9):961-967
Herren et al. 2023 Prospective cohort, 130 patients. 96% implant survival at 2 years (95% CI 90 to 99). Pain at rest fell from 5 to 0 and key-pinch strength rose from 4.5 kg to 7.0 kg. The authors recommend Touch® as the standard procedure for isolated trapeziometacarpal osteoarthritis. PubMed 37310049
Herren et al. 2023, implant versus resection Direct comparison against resection-suspension-interposition arthroplasty. Employed patients returned to work at a mean of 44 days after implant arthroplasty against 84 days after resection. Key-pinch strength 6.8 kg versus 3.1 kg at three months, and 7.0 kg versus 3.9 kg at one year. J Hand Surg Eur Vol 2023 Jul 21
Marks et al. 2026 Cost-utility analysis over one year, 80 implant patients against 39 resection arthroplasty patients. Implant arthroplasty produced higher quality-adjusted life years (0.89 versus 0.85) at lower total cost (USD 26,809 versus USD 33,953), and stayed cost effective in five-year sensitivity analysis. J Hand Surg Am 2026 Jan 28
Gonzalez-Espino et al. 2021 Retrospective series of 92 prostheses. No major complications (dislocation, fracture or loosening). Functional QuickDASH scores not significantly different from age-matched general population. Mean return to work 2.6 months. Hand Surg Rehabil 2021;40(6):760-764
Herren et al. 2025, learning curve 338 Touch® arthroplasties analysed by cumulative sum method. Surgeons reached proficiency between case 33 and case 40, with mean operating times of 39 to 59 minutes. Two-year outcomes and revision rates were no worse for patients operated before proficiency was reached. J Hand Surg Eur Vol 2025 Jun 9
Lyons et al. 2026 Three-round modified Delphi consensus with 16 hand surgeons and hand therapists from the UK and mainland Europe, setting postoperative best practice and return-to-activity timescales for thumb CMC joint replacement. Bone Jt Open 2026;7(7):825-837
Abdoulaye-Diallo et al. 2026 French national hospital discharge data, 2009 to 2024, with two surveys of the French Society for Surgery of the Hand. Trapeziometacarpal arthroplasty accounted for 75.1% of all rhizarthrosis procedures in 2024, and the share of surgeons reporting a predominance of arthroplasty rose from 52.5% in 2018 to 85.9% in 2025. A study of the procedure, not of Touch® specifically. Hand Surg Rehabil 2026;45(3):102619
KeriMedical scientific dossier, September 2026 Collects 94 publications and congress abstracts on CMC1 arthroplasty, of which 56 sit in the Touch®-specific sections, covering peer-reviewed clinical series, congress abstracts, comparisons against trapeziectomy, and pre-clinical work. Full bibliography available to qualifying surgeons on request. Manufacturer documentation
GESY & Cost

GESY Coverage & Pricing in Cyprus

The Touch® CMC Prosthesis is GESY-covered under an active ZC code. When implanted by a participating hand surgeon at a GESY-contracted hospital, the device cost is included in the hospital reimbursement, and patients are not billed separately for the implant.

For self-pay or international patients, OrganoGEN provides hospital quotations on request. We do not publish list prices. Request a quote with your hospital's procurement details.

FAQ

Frequently asked questions

Is the Touch® CMC Prosthesis covered by GESY in Cyprus?
Yes. The Touch® CMC Prosthesis is approved for GESY reimbursement when implanted by a participating hand surgeon at a GESY-contracted hospital. The implant cost is included in the hospital reimbursement.
Who manufactures the Touch® CMC Prosthesis?
KeriMedical SA in Geneva, Switzerland. KeriMedical was founded by hand surgeons and has been part of the Medartis Group since July 2025, operating as a distinct hand-and-wrist brand within the group. OrganoGEN is the exclusive distributor in Cyprus.
What is the dislocation rate of the Touch® CMC Prosthesis?
In a single-surgeon comparative series, there was one dislocation in 184 Touch® prostheses (0.5%) against seven in 168 of the legacy single-mobility Arpe implant (4.2%), P=0.02. Overall complication rates in the same series were 2.7% for Touch® and 6.5% for Arpe (Reyniers et al. 2025, PubMed 41015915). A separate prospective study of 107 cases with more than three years of follow-up reported zero dislocations (Lussiez et al. 2021, J Hand Surg Eur Vol 46(9):961-967).
Is the Touch® implant CE-marked?
Yes. Touch® is CE-marked Class III under EU MDR 2017/745 (notified body 2862). KeriMedical has held continuous CE certification since 2015; the current MDR certificate is valid through 15 February 2028. Touch® additionally holds FDA Premarket Approval P240020 (10 July 2025) for the US market - a useful credential, not a primary positioning point for Cyprus.
Why are 144 configurations needed?
Trapeziometacarpal anatomy varies significantly between patients. The Touch® system combines 6 stem sizes, two cup shapes (spherical and conical) in two diameters, and six neck options (three heights, straight or 15° offset), yielding 144 total configurations. The surgeon matches the implant to anatomy intra-operatively from a single tray rather than committing to a fixed configuration at templating.
What is the polyethylene liner made of and why does it matter?
The Touch® liner is highly cross-linked polyethylene (HXLPE), the same polymer technology used in modern total hip replacements for improved wear resistance. KeriMedical bench testing shows the HXLPE liner retains 97.5% of its volume after 5 million test cycles (approximately ten years of regular thumb usage) compared with 91.1% for standard polyethylene. Touch® is the first dual-mobility CMC1 prosthesis to use HXLPE. Bench testing is not necessarily indicative of clinical performance, but five-to-eight-year prospective clinical follow-up data is published.
What functional improvement do patients see after Touch® CMC arthroplasty?
In the largest published prospective Touch® series with more than three years of follow-up, mean pain on a 0 to 10 visual analogue scale dropped from 7.4 to 0.8, the Kapandji thumb-opposition score improved from 8.0 to 9.4, the QuickDASH disability score improved from 38 to 20, and key-pinch strength increased from 3.5 kg to 5.5 kg. 95% of patients reported being very satisfied or satisfied with the functional outcome (Lussiez et al. 2021). A separate 92-prosthesis series reported mean return to work at 2.6 months (Gonzalez-Espino et al. 2021).
How long does a Touch® CMC prosthesis last?
Published implant survival is 96% at two years (130 patients, Herren et al. 2023) and 96% at five years (125 patients, Herren et al. 2026, 95% CI 92 to 100). The longest Touch®-specific follow-up published to date covers 61 prostheses at a mean of 6.5 years, with a single revision for cup loosening at seven years and every patient satisfied or very satisfied (Falaise and Boulat 2025). Where a prosthesis does need revising, the salvage operation is a standard trapeziectomy, and published outcomes of that salvage are comparable to a primary trapeziectomy.
How soon can patients return to work and normal activities?
In a direct comparison against resection arthroplasty, employed patients returned to work at a mean of 44 days after Touch® implant arthroplasty against 84 days after resection (Herren et al. 2023). A separate series of 179 patients reported a median of 51 days, with no significant difference between office workers and manual workers (Tchurukdichian et al. 2025). A 2026 European Delphi consensus sets the expected timescales at two weeks for light tasks, four weeks for driving and moderate tasks, and six to eight weeks for heavy tasks (Lyons et al. 2026).
How does Touch® compare with trapeziectomy?
In a comparative study (Herren et al. 2023), recovery was faster and the thumb stronger after Touch® than after trapeziectomy. Patients returned to work roughly forty days earlier and had higher key-pinch strength, 6.8 kg against 3.1 kg at three months and 7.0 kg against 3.9 kg at one year. Thumb column length is preserved rather than resected, which in a case-control study also corrected pre-existing metacarpophalangeal hyperextension without a second procedure (Schindele et al. 2025). At one year, overall hand-function scores converge between the two operations, so the case for arthroplasty rests on speed of recovery, strength and preservation of thumb length rather than on a better end point. A 2026 cost-utility analysis found implant arthroplasty both lower in total cost and higher in quality-adjusted life years than resection arthroplasty over one year (Marks et al. 2026).
Where can patients have Touch® CMC arthroplasty in Cyprus?
OrganoGEN supplies the Touch® system to GESY-contracted hospitals across Cyprus. Contact us for the current list of participating hand surgeons in Limassol, Nicosia, Larnaca, Paphos, and Famagusta.
More in Hand & Wrist

Related products